Agios Pharmaceuticals, Inc. has already been working on increasing screening for rare hereditary anemias, and now that the US Food and Drug Administration has approved its Pyrukynd (mitapivat) for patients with pyruvate kinase (PK) deficiency, the company is trying to more than double the rate of patients currently being diagnosed.
Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
Reimbursement Challenges
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
